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Phthalates, the diesters of phthalic acid, are 
ubiquitous in the environment, with annual 
global production at more than three mil-
lion metric tons (Bizzari et al. 2000). Since 
their introduction in the 1930s, phthalates 
have been used as plasticizers and in cosmetics, 
food containers, medicine coatings, lubricants, 
adhesives, ink, medical devices, and tubing 
(Hauser and Calafat 2005). Certain phthalates 
have been shown to be endocrine disruptors 
in laboratory animals. The toxicity of phtha-
lates in animals is related to the structure of 
the phthalate, the dose administered, and the 
animal’s age at exposure (Foster 2006; Foster 
et al. 2001). Rat testicular toxicity shows dif-
ferential sensitivity based on the length of the 
phthalate alkyl side chain (Foster et al. 1980). 
Many of the effects in animals are seen at high, 
non-environmentally relevant doses (Parks 
et al. 2000). Young male rats exposed in utero 
or pubertally are more sensitive to the effects 
of phthalates than are adult animals (Foster 
2006). Knowledge of the exposure of breast-
feeding populations to phthalates is limited, 
and the distribution of phthalates in various 
bodily fluids during lactation is of interest 
for childhood nutrition and for exposure and 
health risk assessment.
Biomonitoring studies have shown phtha-
late exposure is widespread in humans (Duty 
et al. 2005; Silva et al. 2004). Phthalate expo-
sure occurs via dermal contact, intravenous 
injection, inhalation, or ingestion. After expo-
sure, phthalates are metabolized and excreted 
with an elimination half-life of 8–10 hr in 
adults (Bruns-Weller and Pfordt 1999). The 
half-life of phthalates in children or lactating 
women is unknown. All phthalates are first 
metabolized to their hydrolytic monoesters, 
and some phthalates can be further metabolized 
to their oxidative metabolites. The tendency 
to form oxidative metabolites increases as the 
molecular weight of the phthalate increases. 
Traditionally, the hydrolytic monoesters have 
been measured because they are considered to 
be biologically active. However, the exclusive 
use of the hydrolytic monoester metabolites 
underrepresents exposure to high-molecular-
weight phthalates (Högberg et al. 2008; Silva 
et al. 2005b).
Few studies have evaluated phthalate con-
centrations in pregnant and lactating women. 
Monoethyl phthalate (MEP), monobu-
tyl phthalate (MBP), monobenzyl phthalate 
(MBzP), and mono(2-ethylhexyl) phthalate 
(MEHP) have been detected in urine speci-
mens, and their diester parent compounds in 
house dust samples, from pregnant women 
living in New York City (Adibi et al. 2003, 
2008). Breast milk has been reported to 
contain phthalate metabolite monoesters in 
samples from Denmark/Finland (Main et al. 
2006), Sweden (Högberg et al. 2008), and 
Italy (Latini et al. 2003). Calafat et al. (2004), 
in a method development study, followed the 
monoester and oxidative metabolites of three 
pooled U.S. human milk samples and found 
that most of the oxidative metabolites were at 
or below the limit of detection (LOD). The 
objectives of the present study were to accu-
rately measure and compare the concentrations 
of oxidative monoester phthalate metabolites 
in milk and surrogate fluids (serum, saliva, and 
urine) of 33 lactating North Carolina (NC) 
women. We explored the interrelationship of 
phthalate metabolites detected in urine and 
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Ba c k g r o u n d: Phthalates are ubiquitous in the environment, but concentrations in multiple media 
from breast-feeding U.S. women have not been evaluated.
oBjectives: The objective of this study was to accurately measure and compare the concentrations 
of oxidative monoester phthalate metabolites in milk and surrogate fluids (serum, saliva, and urine) 
of 33 lactating North Carolina women.
Me t h o d s : We analyzed serum, saliva, urine, and milk for the oxidative phthalate metabolites 
mono(3-carboxypropyl) phthalate, mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono(2-
ethyl-5-hydroxyhexyl) phthalate, and mono(2-ethyl-5-oxohexyl) phthalate using isotope-dilution 
high-performance liquid chromatography tandem mass spectroscopy. Because only urine lacks 
esterases, we analyzed it for the hydrolytic phthalate monoesters.
re s u l t s: We detected phthalate metabolites in few milk (< 10%) and saliva samples. MECPP was 
detected in > 80% of serum samples, but other metabolites were less common (3–22%). Seven 
of the 10 urinary metabolites were detectable in ≥ 85% of samples. Monoethyl phthalate had 
the highest mean concentration in urine. Metabolite concentrations differed by body fluid (urine 
> serum > milk and saliva). Questionnaire data suggest that frequent nail polish use, immuno-
globulin A, and fasting serum glucose and triglyceride levels were increased among women with 
higher concentrations of urinary and/or serum phthalate metabolites; motor vehicle age was 
inversely correlated with certain urinary phthalate concentrations.
co n c l u s i o n s: Our data suggest that phthalate metabolites are most frequently detected in urine of 
lactating women and are less often detected in serum, milk, or saliva. Urinary phthalate concentra-
tions reflect maternal exposure and do not represent the concentrations of oxidative metabolites in 
other body fluids, especially milk.
key w o r d s : biomonitoring, breast milk, lactation, MAMA study, phthalates, saliva, serum, urine. 
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serum, as well as potential associations with 
questionnaire exposure measures.
Materials and Methods
Use of human subjects. The U.S. Environmental 
Protection Agency (U.S. EPA) conducted 
the Methods Advancement for Milk Analysis 
(MAMA) study to evaluate the concentrations 
of endogenous and environmental components 
in human milk and to compare these concen-
trations to those in surrogate media includ-
ing serum, saliva, and urine. We designed the 
MAMA study as a smaller methods devel-
opment pilot for the longitudinal National 
Children’s Study that will follow 100,000 chil-
dren from preconception to age 21 (Landrigan 
et al. 2006; National Children’s Study 
2008). The MAMA study monitored 33 NC 
women over two time periods during lacta-
tion (2–7 weeks postpartum and 3–4 months 
postpartum). The participation of human 
subjects in the MAMA study was approved 
by the Institutional Review Boards (IRB) of 
the University of North Carolina at Chapel 
Hill School of Medicine (IRB no. 03-EPA-
207) and the Centers for Disease Control and 
Prevention (CDC; IRB no. 3961). We briefed 
each woman on the study goals, risks, and 
inclusion/exclusion criteria and participated in 
informed consent (verbally and written) before 
completion of a comprehensive questionnaire, 
which did not include questions pertaining to 
the offspring of MAMA participants.
The women were recruited by an EPA 
contractor (Westat Inc., Chapel Hill, NC) via 
newspaper advertisements, university e-mail 
publications, and fliers distributed to clini-
cians specializing in women’s health or pedi-
atrics. The women participated in the study 
at the EPA’s Human Studies Facility clinic 
(Chapel Hill, NC) between December 2004 
and July 2005.
Questionnaire. We administered a ques-
tionnaire about maternal exposure, occupation, 
residence, diet, and lifestyle to participants at 
the first clinic visit only. We designed the ques-
tions to address potential routes of exposure to 
multiple environmental chemicals (phthalates, 
phenols, perfluoroalkyl compounds, persistent 
organic pollutants, metals, and brominated 
flame retardants). As a pilot study, the MAMA 
questionnaire asked discrete questions (not 
open-ended) based on common exposures likely 
to be relevant to the general population, but 
did not independently validate the questions. 
We also compared biologics (serum and milk 
hormones, cytokines, glucose, triglycerides, 
and immunoglobulins), as previously reported 
(Hines et al. 2007), with questionnaire data and 
phthalate metabo  lite concentrations, paying 
special attention to end points that have been 
reported to be pertinent to phthalate exposure.
Study design and sample collection. We 
recruited healthy, English-speaking women 
between 18 and 38 years of age who were 
breast-feeding their first, second, or third child. 
We did not require mothers to exclusively 
breast-feed. We asked them to fast for 1.5 hr 
before donating milk, saliva, urine, and serum 
at two established collection periods: 2–7 weeks 
and 3–4 months postpartum (visit 1 milk sam-
ples, n = 18; visit 2 milk samples, n = 20; visit 
1 other fluids, n = 33; visit 2 other fluids, n = 
30). We typically collected the urine specimen 
first, followed by serum, milk, and saliva. We 
recorded the sampling details, including time 
of day (between 0900 hr and 1400 hr) and the 
amount of bodily fluid collected, in the col-
lection log. Milk (90 mL, or ~3 ounces) was 
expressed in the EPA clinic using a commer-
cially available electric breast pump (Medela, 
McHenry, IL). All containers used in the col-
lection and storage of the samples in this study 
were known to be phthalate-free based on ear-
lier analyses by the CDC (data not shown). 
Before the MAMA study, we performed a 
leaching study in our lab to determine if any 
additional phthalates could be contributed to a 
milk sample collected by the breast pump cho-
sen for this study (Hines EP, et al., unpublished 
data). This leaching study showed no significant 
difference in phthalate metabolite concentra-
tions after passing through a breast pump. Milk 
was pumped into di(2-ethylhexyl) phthalate 
(DEHP)-free polypropylene bottles, divided 
into 3 mL aliquots in polypropylene tubes, and 
treated with 1 M phosphoric acid (125 µL/
mL milk) to neutralize esterases. The women 
also donated about 20 mL of blood, which was 
collected into nonheparinized glass Vacutainer 
(Becton Dickinson, Franklin Lakes, NJ) tubes 
by an EPA nurse via venipuncture of the 
median cubital vein. After 1 hr at room tem-
perature to allow for clotting, we spun blood 
samples at 3,000 rpm for 15 min at room tem-
perature and collected the serum. If fibrin clot-
ting of the serum layer occurred after the initial 
centrifugation, we ruptured the clots and centri-
fuged samples a second time. We treated serum 
samples with phosphoric acid as described 
above for milk. Saliva was collected in six poly-
propylene salivettes (Sarstedt AG, Nümbrecht, 
Germany) as described previously (Ferrari 
et al. 2008), and 3 mL of saliva was collected 
and transferred to a polypropylene cryovial 
and treated with phosphoric acid as described 
above. Similarly, we collected urine into poly-
propylene collection cups without further treat-
ment and aliquoted (3 mL) into polypropylene 
cryovials. We stored all samples at –20°C and 
shipped them on dry ice to the CDC’s Division 
of Laboratory Sciences, National Center for 
Environmental Health (Atlanta, GA), for analy-
sis. At the CDC, all samples were stored at or 
below –20°C until analyzed.
Methods. We performed the preparation of 
standard solutions, quality control (QC) veri-
fication, sample preparation, and instrumental 
analyses as previously described (Calafat et al. 
2004) with slight modification of the sam-
ple preparation as described herein. Sample 
analyses involved enzymatic deconjugation 
of the glucuronidated phthalates, automated 
solid-phase extraction, and separation using 
isotope-dilution high-performance liquid chro-
matography followed by tandem mass spec-
trometry (milk, Calafat et al. 2004; urine, Kato 
et al. 2004; serum and saliva, Silva et al. 2005a, 
2005b). This high-throughput approach allows 
for simultaneous detection of at least 10 phtha-
late metabolites. We used internal standards 
(isotope-labeled and conjugated) to increase 
measurement precision and accuracy. We ran 
QC and reagent blank samples with unknown 
samples to monitor method performance.
We measured phthalate hydrolytic 
monoesters and oxidative metabolites in 
urine. Breast milk, serum, and saliva hydro-
lytic monoesters, were measured and some-
times detected but are not reported because 
environmental contamination of diesters and 
nearly concomitant generation of monoesters 
from these diesters can lead to an inflated rep-
resentation of the milk (or surrogate fluid) 
monoester phthalate pool (Calafat et al. 2004). 
Environmental contamination can easily occur 
because serum is collected via Vacutainer and 
requires time to clot before multiple centrif-
ugations occur, after which acid is added to 
samples. Similarly, milk collection is a multi-
ple-step collection process with the possibil-
ity for environmental contamination during 
that time. We report the concentrations of 
oxidative metabolites for milk, serum, saliva, 
and urine. Milk, saliva, and serum lower lim-
its of quantification (LOQs) were 1.07 µg/L 
[mono(3-carboxypropyl) phthalate (MCPP)], 
0.80 µg/L [mono(2-ethyl-5-carboxypentyl) 
phthalate (MECPP)], 1.07 µg/L [mono(2-
ethyl-5-hydroxyhexyl) phthalate (MEHHP)], 
and 0.80 µg/L [mono(2-ethyl-5-oxohexyl) 
phthalate (MEOHP)]. In urine, the LODs 
were 0.45 µg/L (MBP), 0.40 µg/L (MBzP), 
0.32 µg/L (MCPP), 0.40 µg/L (MECPP), 0.11 
µg/L (MEHHP), 0.25 µg/L (MEHP), 0.16 
µg/L (MEOHP), 0.26 µg/L (MEP), 1.00 µg/L 
[monomethyl phthalate (MMP)], and 0.90 
µg/L [monoisobutyl phthalate (MiBP)]. Breast 
milk phthalate metabolite concentrations can 
fall below LOD due to concentration factors. 
We report concentrations as micrograms per 
liter in serum, milk, and saliva, and in urine 
both as micrograms per liter and as micro-
grams per gram creatinine after   creatinine 
adjustment to correct for urine dilution. We 
analyzed urine samples for creatinine using a 
Beckman Synchron AS/ASTRA clinical ana-
lyzer (Beckman Instruments, Inc., Brea, CA) 
at the CDC. A previous study (Adibi et al. 
2008) in pregnant women suggested that spe-
cific gravity was a better indicator of urine 
dilution than is creatinine. Because this was Hines et al.
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unknown at the time of our data analysis, we 
measured creatinine. MEP, the smallest of the 
metabolites reported here, may have a different 
excretion pattern than other phthalates, and 
thus creatinine adjustment may alter MEP’s 
values differently than those of other phthalate 
metabolites (Boeniger et al. 1993; Duty et al. 
2003). Thus, most comparisons in this article 
focus on urine concentrations of phthalates 
independent of creatinine adjustment.
Statistics. We did not compare phthalate 
metabolites across matrices when we detected 
phthalates in < 50% of samples (Baccarelli et al. 
2005). We assessed Spearman correlations to 
determine relationships within and between 
phthalate metabolites, comparing visit 1 and 
visit 2 unadjusted and creatinine-adjusted uri-
nary concentrations. We treated values lower 
than the LOD as missing for all analyses. We 
used rank order correlations to account for the 
nonparametric distribution of the phthalate 
metabolites. Where serum phthalate metabolite 
concentrations for visits 1 and 2 were detectable, 
we compared serum and urine concentrations 
using Spearman correlations. For categorical 
questionnaire measures, we used one-way anal-
ysis of variance to test for differences in mean 
phthalate metabolite concentrations, using both 
the original metabolite levels and repeated after 
transforming the data to a log-normal distribu-
tion with a mean of 0 and standard deviation 
of 1. The association between continuous ques-
tionnaire measures and phthalate metabolite 
concentrations was assessed with Spearman cor-
relations. We used paired t-tests to compare 
the total urinary metabolite concentrations and 
a subset of DEHP metabolite concentrations 
from visit 1 to visit 2. No adjustments were 
made for multiple comparisons. We conducted 
all analyses using SAS Enterprise Guide 4.1 
(SAS Institute Inc. 2006).
Results
Phthalate metabolites detected in MAMA sam­
ples. Table 1 lists the percentages of detect-
able phthalate metabolite concentrations. Of 
the total milk samples, 3%, 8%, 5%, and 
2% contained detectable concentrations of 
MCPP, MECPP, MEHHP, and MEOHP, 
respectively. Of the total saliva samples, 2%, 
Table 1. Various phthalate metabolites detected (% > LOD) in samples from lactating NC women: U.S. EPA 
MAMA study, 2004–2005.
  Phthalate metabolite
Fluid  MCPP  MECPP  MEHHP  MEOHP  MBP  MBzP  MEHP  MEP  MMP  MiBP  No.a
Milk 
  Visit 1  6  8  8  4  NA  NA  NA  NA  NA  NA  18 
  Visit 2  0  8  3  0  NA  NA  NA  NA  NA  NA  20 
  Total  3  8  5  2  NA  NA  NA  NA  NA  NA  38
Serum 
  Visit 1  3  84  22  19  NA  NA  NA  NA  NA  NA  32 
  Visit 2  3  93  13  13  NA  NA  NA  NA  NA  NA  30 
  Total  3  87  17  14  NA  NA  NA  NA  NA  NA  62
Saliva 
  Visit 1  0  0  0  0  NA  NA  NA  NA  NA  NA  32 
  Visit 2  3  3  0  0  NA  NA  NA  NA  NA  NA  30 
  Total  2  2  0  0  NA  NA  NA  NA  NA  NA  62
Urine 
  Visit 1  100  100  100  100  97  100  91  100  18  97  33 
  Visit 2  93  100  93  93  80  100  50  100  7  67  30 
  Total  97  100  97  97  89  100  71  100  13  82  63
NA, not analyzed.
aNumber of samples measured for each end point.
Figure 1. Mean ± SE phthalate metabolite levels (µg/L) from visit 1 and visit 2 serum (sMECPP) and urine 
(all other metabolites).
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Table 2. Median and selected percentiles of phthalate metabolite concentrations in urine from lactating 
NC women: U.S. EPA MAMA Study, 2004–2005. 
Phthalate     10th  25th    75th  90th  95th 
metabolite  Visit   percentile  percentile  Median  percentile  percentile  percentile  No.a
MBP  1  1.3 (9.7)  6.8 (13.4)  14 (18.3)  21.8 (28.1)  38.9 (34.9)  53.5 (40.8)  33
  2  < LOD (4.3)  2.1 (11.0)  6.6 (18.2)  9.5 (48.0)  94.2 (71.3)  155.9 (133.0)  30
MBzP  1  1.6 (6.3)  4.2 (9.2)  9.6 (14.4)  27.7 (32.1)  52.6 (49.7)  75.6 (70.2)  33
  2  1.0 (5.1)  3.8 (7.6)  11.0 (13.4)  22.5 (27.2)  53.2 (56.4)  141.1 (62.6)  30
MCPP  1  0.6 (2.3)  1.5 (2.9)  3.2 (3.5)  5.4 (6.1)  7.6 (7.2)  11.4 (17.9)  33
  2  0.4 (1.3)  0.8 (2.7)  3.4 (3.7)  6.2 (7.1)  14.2 (9.0)  18.2 (10.2)  30
MECPP  1  4.2 (16.8)  12.8 (23.0)  27.3 (36.8)  51.9 (89.1)  218.3 (152.9)  364.4 (247.9)  33
  2  3.1 (12.7)  6.7 (18.3)  24.8 (32.5)  58.0 (64.4)  138.9 (102.5)  236.9 (134.8)  30
MEHHP  1  3.6 (10.5)  9.8 (14.4)  18.6 (24.5)  28.8 (43.9)  139.4 (153.9)  336.2 (183.0)  33
  2  1.4 (4.5)  4.2 (10.5)  10.9 (17.0)  32.6 (43.6)  107.8 (74.0)  181.9 (80.7)  30
MEHP  1  1.5 (1.9)  2.1 (3.4)  3.0 (7.6)  6.2 (15.1)  18.1 (30.3)  86.2 (46.9)  33
  2  < LOD (1.3)  < LOD (1.6)  < LOD (3.6)  4.3 (11.9)  13.4 (17.0)  21.1 (58.0)  30
MEOHP  1  2.6 (7.3)  6.5 (10.6)  12.0 (17.9)  19.3 (29.4)  77.1 (91.5)  224.2 (122.1)  33
  2  1.3 (4.3)  2.9 (8.6)  8.4 (13.5)  20.4 (32.5)  59.6 (43.9)  77.8 (45.2)  30
MEP  1  9.2 (28.7)  29.5 (48.5)  73.1 (145.0)  145.0 (218.5)  442.5 (535.1)  6891.8 (3155.6)  33
  2  13.2 (29.0)  23.2 (63.9)  74.3 (113.0)  275.2 (249.5)  996.1 (661.8)  1662.2 (2444.4)  30
MMP   1  < LOD (2.2)  < LOD (3.8)  < LOD (4.1)  < LOD (10.7)  2.6 (97.1)  4.5 (97.1)  33
  2  < LOD (3.5)  < LOD (3.5)  < LOD (4.9)  < LOD (6.4)  < LOD (6.4)  4.8 (6.4)  30
MiBP  1  0.7 (2.6)  1.5 (3.8)  3.8 (5.2)  6.6 (7.0)  10.0 (9.4)  12.1 (13.9)  33
  2  0.6 (1.0)  0.6 (1.9)  2.1 (3.4)  4.7 (7.6)  13.0 (10.5)  19.0 (12.2)  30
Abbreviations: U, unadjusted for creatinine (µg/L); UA, creatinine adjusted (µg/g). Values shown are U(UA).
aNumbers of samples measured for each end point.
Figure 2. Urinary concentrations (mean ± SE) of 
total phthalate metabolites (Pht) and DEHP phtha-
late metabolites (µg/L, unadjusted), by visit.
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2%, 0%, and 0% contained detectable con-
centrations of MCPP, MECPP, MEHHP, 
and MEOHP, respectively. We detected uri-
nary phthalate metabolites in > 85% of the 
urine samples, with the exception of MMP, 
MEHP, and MiBP (Table 1). We detected 
MCPP, MECPP, MEHHP, and MEOHP in 
3%, 87%, 17%, and 14% of total serum sam-
ples, respectively. Because we found MECPP 
in > 50% of serum samples, we compared it 
across matrices (serum vs. urine).
Concentrations of phthalate metabolites in 
human milk. We detected MCPP, MECPP, 
MEHHP, and MEOHP in very few breast 
milk samples (in low parts per billion con-
centrations). When we considered the data 
from both collection times, we detected two 
analytes in 1 of 38 samples from 65 analytic 
runs (MCPP, 0.2 µg/L; MEOHP, 0.3 µg/L). 
We detected MECPP in 5 of 39 samples from 
65 analytic runs (0.1, 0.1, 0.1, 0.3, and 0.4 
µg/L), and MEHHP in 3 of 39 samples from 
65 analytic runs (0.2, 0.3, and 0.3 µg/L). There 
appeared to be insignificant concentrations of 
phthalate oxidative metabolites in breast milk 
collected in this study.
Concentrations of phthalate metabolites 
in serum. We measured the oxidative phtha-
late monoesters MCPP, MECPP, MEHHP, 
and MEOHP in human serum. MECPP was 
detected in the highest amounts with a mean of 
2.0 µg/L (visit 1) and 2.3 µg/L (visit 2) (range, 
< LOD to 13.7 µg/L). We detected the other 
metabolites less frequently, and their means 
were close to their respective LOQs. Figure 1 
shows serum MECPP concentrations for visits 
1 and 2.
Concentrations of phthalate metabolites in 
saliva. We detected only two phthalate metab-
olites (2.2 µg/L MCPP and 2.3 µg/L MECPP) 
in a single saliva sample from one woman on 
one visit. All other phthalate concentrations 
were undetectable. These data suggest limited 
transfer of oxidative phthalate metabolites into 
saliva in a fasting breast-feeding mother.
Concentrations of phthalate metabolites 
in urine. Table 2 shows median and selected 
percentiles of phthalate metabolite concentra-
tions in urine. Urine, unlike the other biologic 
media analyzed in this study, does not contain 
esterases, which can break down parent diester 
phthalates to hydrolytic monoester metabolites. 
Therefore, we report all monoester metabolite 
concentrations in urine because contamination 
contribution to the monoester metabolite pool 
is unlikely. Four of these metabolites, MEHP, 
MECPP, MEHHP, and MEOHP, are derived 
from the same parent compound, DEHP (as 
detailed in Koch et al. 2005). MEP concentra-
tions, on average, were 10-fold higher than the 
next highest phthalate metabolite (Figure 1).
Total urinary phthalate load. Figure 2 
reports total phthalate metabolite concentra-
tions and the total concentration of DEHP 
metabolites in urine, by visit. We measured 
multiple DEHP metabolites in this study, 
including MEHP, its monoester metabo-
lite, and its oxidative metabolites (MEHHP, 
MEOHP, and MECPP). We found no signifi-
cant change in both total and DEHP-derived 
metabolites between visits (by two-tailed t-test, 
p < 0.05) because urinary metabolite concentra-
tions tended to vary greatly within each subject 
across the visits.
Correlations. Between- and within-visit 
correlations—individual urinary metabolites. 
As anticipated, all of the unadjusted urinary 
metabolite concentrations were significantly 
correlated with the creatinine-adjusted levels 
from the same visit (Spearman’s R ranged from 
0.50 to 0.78; data not shown). MMP was not 
correlated between visits, which may be con-
founded by MMP detected in less than 20% of 
the samples. Visit 1 concentrations of the other 
nine urinary metabolites were significantly cor-
related with their measurements at visit 2 when 
examining the unadjusted values (Table 3), 
but only MBzP and MEP were significantly 
correlated between visits 1 and 2 for creatinine-
adjusted concentrations.
Comparing  serum  with  urinary 
metabolites. Only MECPP had sufficient 
detection frequency in serum to allow for com-
parison between urine and serum concentra-
tions (Table 4). Serum and urine MECPP 
concentrations were correlated within visits 
but not between visits (Spearman R = –0.22, 
p = 0.27, n = 28). Table 5 shows the relation 
of serum MECPP concentrations to those of 
other DEHP metabolites in urine. At visit 1, 
MECPP in serum was correlated with urinary 
MEHHP (unadjusted only), MEHP (crea-
tinine-adjusted only), and MEOHP (both 
unadjusted and adjusted concentrations). At 
visit 2, MECPP in serum was correlated with 
MEHHP in urine (unadjusted and adjusted 
for creatinine) and with MEOHP (unadjusted 
only). Serum MECPP was not correlated with 
urinary MEHP at visit 2. No serum measure 
was correlated with any urine measure from 
the other visit.
Correlations between urinary metabolites 
of DEHP. Within visits, correlations among 
the DEHP urine metabolites (the hydrolytic 
monoester MEHP and three of its oxidative 
products, MECPP, MEHHP, and MEOHP) 
were strongest for MECPP and MEHHP 
(Spearman’s R ranged from 0.96 to 0.61; 
data not shown) and MEOHP (Spearman’s R 
ranged from 0.97 to 0.61; data not shown). 
Unadjusted MEHP concentrations were cor-
related with both unadjusted MECPP (R = 
0.62, p < 0.001) and adjusted MECPP con-
centrations (R = 0.48, p < 0.01) at visit 1 but 
not at visit 2. MEOHP and MEHHP were 
also generally well correlated within visits (R 
ranged from 0.98 to 0.62; data not shown). 
Overall, the DEHP metabo  lites correlated well 
with each other, with the oxidative metabolites 
having stronger correlation among themselves 
than with the monoester MEHP.
Correlations of phthalate metabolites 
with questionnaire data. We administered 
the questionnaire only at visit 1, so we com-
pared questionnaire data with visit 1 phthalate 
metabolite concentrations. Because previous 
work has shown that creatinine is not the best 
way to adjust urinary phthalate levels (Adibi 
et al. 2008) and because creatinine-adjusted 
and nonadjusted phthalate values correlate 
within visits, we used nonadjusted urinary con-
centrations for the remainder of the data analy-
sis. Most of the questionnaire variables were 
not significantly related to metabolite concen-
trations, including the number of prior births, 
prior breast-feeding, use of prescription or over-
the-counter medication, new furniture, blinds, 
and use of glues or solvents, hair products, and 
paint. Using the untransformed metabolite 
data, serum MECPP was significantly different 
by income category, with the highest metabo-
lite concentrations in the middle income group 
($50,000–70,000), but after log-normal trans-
formation, this was no longer statistically sig-
nificant (p = 0.15). We observed no relation 
for income with any of the urinary metabolite 
concentrations. Untransformed serum MECPP 
concentrations differed significantly by race   
Table 3. Spearman correlations for visit 1 versus visit 2 for urinary phthalate metabolites.
Correlation variable  MBP  MBzP  MCPP  MECPP  MEHHP  MEHP  MEOHP  MEP  MiBP
Unadjusted 
  Rho  0.47  0.71  0.44  0.48  0.38  0.63  0.45  0.60  0.58 
  p-Value  0.02  < 0.0001  0.01  0.008  0.04  0.01  0.02  0.0005  0.0008 
  No.   24  30  30  30  30  15  28  30  30
Creatinine-adjusted 
  Rho  0.24  0.54  0.31  0.29  0.24  0.48  0.20  0.50  0.33 
  p-Value  0.27  0.002  0.09  0.11  0.20  0.07  0.31  0.005  0.07 
  No.   24  30  30  30  30   15  28  30   30
Table 4. Spearman correlations between serum 
and unadjusted (U) and creatinine-adjusted (UA) 
urine MECPP levels for visits 1 and 2.
  Visit 1  Visit 2 
Serum  U  UA  U  UA
Visit 1  0.45  0.74  –0.12  0.08
 p -Value  0.01  < 0.0001  0.53   0.70
  No.  31  31  28   28
Visit 2  0.23  0.01  0.62  0.56
 p -Value   0.21  0.97  0.0002   0.001
  No.   30  30  3   30Hines et al.
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(F = 4.90, p = 0.04, df = 1), with higher mean 
levels among nonwhites (mean ± SD = 5.03 ± 
5.64) compared with white mothers (1.84 ± 
2.09), but again, this was not significant after 
log transformation of the raw data (p = 0.13). 
Mean levels of urinary MEP increased signifi-
cantly according to self-reported nail polish 
use in the untransformed data, with a mean 
level of 2873.8 (SD = 1826.0) for women who 
“often” use nail polish compared with 50.5 
(SD = 11.6) for women who “never” use it. 
After log transformation, we observed addi-
tional associations between nail polish use 
(any vs. none) and MBP (p < 0.001), MBzP 
(p < 0.01), MECPP (p = 0.01), MEHHP 
(p < 0.01), MEOHP (p < 0.01), and the sum 
of DEHP metabolites (p < 0.01). Interestingly, 
MECPP, MEHHP, MEOHP, and MiBP con-
centrations were all inversely correlated with 
the age of the primary car driven by the partici-
pants (Table 6); women who drive newer cars 
appear to have higher urinary concentrations of 
these phthalate metabolites.
Immune-related correlations. Serum 
immunoglobulin A (IgA) and urinary MBP 
at visit 1 were correlated (rho = 0.36, p = 
0.04, n = 32). No other phthalate metabolites 
  correlated with serum IgA. Serum IgM, IgE, 
and IgG showed no significant correlations 
with phthalate metabolite concentrations.
Glucose-related correlations. Multiple 
glucose-related end points showed correla-
tions with phthalate exposure. Although only 
two mothers had reported gestational diabetes, 
both their serum and urine concentrations 
of MECPP were more than three times the 
mean of mothers without reported gestational 
diabetes (serum, 6.8 ng/mL vs. 1.9 ng/mL; 
urine, 212.9 ng/mL vs. 59.8 ng/mL). Several 
of the urinary DEHP metabolites (MECPP, 
MEHP, MEHHP, and MEOHP) in visit 1 
samples correlated with visit 1 serum glucose 
(Table 7); only three of the MAMA partici-
pants had   glucose levels outside the normal 
range (≥ 100 mg/dL at fasting), and only one 
of these three reported gestational diabetes.
Triglyceride-related correlations. Multiple 
phthalate metabolites showed significant posi-
tive correlations with serum triglycerides. Visit 
1 urinary MEHP, MECPP, MEHHP, and 
MEOHP concentrations all correlated with 
visit 1 serum triglyceride concentrations 
(Table 8). None of the other phthalate metab-
olites correlated with serum triglycerides at visit 
1. Eight of the 33 women had serum triglycer-
ide levels defined as high for healthy nonlactat-
ing adults; normal levels are not available for 
lactating women.
Nonsignificant findings. Comparing 
phthalate MAMA metabolite concentra-
tions (urine and serum) with a biologics panel 
(Hines et al. 2007) from serum collected at 
visit 1, which included IgG, IgE, IgM, prolac-
tin, estradiol, tumor necrosis factor-alpha, and 
interleukin-6, yielded nonsignificant findings.
Discussion
Lactational exposure of U.S. infants to phtha-
lates has largely been overlooked. The MAMA 
study is the first to evaluate phthalate concen-
trations in multiple body fluids from a con-
venience sample of lactating women in the 
United States at two time points, focusing on 
oxidative phthalate metabolites in serum, milk, 
and saliva and both oxidative and hydrolytic 
monoester metabolites in urine. We detected 
phthalate oxidative metabolites (MCPP, 
MECPP, MEHHP, and MEOHP) in very 
few milk samples, and those that we detected 
were near the LOQ. Because of the methods 
development nature of this study, we analyzed 
breast milk samples from 55% of mothers at 
visit 1 and 67% at visit 2, in contrast to other 
fluids that we analyzed for nearly every woman. 
Nevertheless, very few milk samples had any 
detectable phthalate metabolites, making com-
parisons with other biologic fluids impossi-
ble. Given these findings, milk is unlikely to 
contain oxidative phthalate metabolites, and 
investigators interested in exposure assessment 
in lactating women should focus on collecting 
urine. Further, we detected only two metabo-
lites in saliva from one woman on one visit; all 
other phthalates were undetectable in saliva. 
This suggests that there is little transfer of 
phthalates to saliva of fasting lactating women.
Several phthalate assessment studies 
have been conducted previously, including a 
Canadian study on milk diesters (Zhu et al. 
2006), a Japanese study on breast milk hydro-
lytic monoesters (Takatori et al. 2007), and an 
Italian study on diesters in milk (Latini et al. 
2003). A previous study on phthalate metabo-
lites in multiple media (milk, urine, and serum) 
from Swedish women abstaining from skin 
care product use collected milk and 1 week 
later collected urine and serum (Högberg et al. 
2008). In this study, we collected all body flu-
ids at one time in women with no personal care 
product use limitations. Our rates of detection 
are in agreement with previous studies, includ-
ing Högberg et al.’s (2008) findings, except 
that in this study we detected MiBP less fre-
quently than did the Adibi et al. (2008) study. 
In Main et al.’s (2006) study of Danish and 
Finnish breast milk, samples used for hydro-
lytic monoester phthalate metabolite analysis 
were pooled from multiple small hindmilk col-
lections 1–3 months postpartum.
Urinary phthalate concentrations in the 
present study were comparable with those 
in studies of pregnant women in the United 
States and abroad (Adibi et al. 2003; Swan 
et al. 2005), with MEP concentrations in these 
studies 10-fold greater than other monoester 
metabolites. Phthalate exposure comparisons 
were made using non-creatinine-adjusted values 
based on earlier work by Adibi et al. (2008). 
Mean urinary MEP and MEHP concentra-
tions detected in this study were similar (2-fold 
higher) to those in females or people 20–39 
years of age as reported for the 1999–2000 
National Health and Nutrition Examination 
Survey (NHANES) (Silva et al. 2004). Urinary 
MBP and MBzP concentrations in this study 
were also similar to the NHANES values.
Several human studies have reported cor-
relations between possible health effects and 
low concentrations of phthalate metabolites. 
Duty et al. (2003) found a dose–response rela-
tionship between urinary MBP or MBzP con-
centrations and sperm motility and/or sperm 
concentration (indicators of sperm quality). 
Table 5. Spearman correlations between serum MECPP and other DEHP metabolite concentrations in urine.
  MEHHP  MEHP  MEOHP 
Sample  U  UA  U  UA  U  UA
Visit 1  0.43  –0.11  0.33  0.38  0.39  0.67
p-Value  0.02  0.57  0.08  0.04  0.03  < 0.0001
No.   31  28  28  28  31  31
Visit 2  0.50  0.43  0.31  0.18  0.42  0.35
p-Value  0.005  0.02  0.27  0.51  0.03  0.07
No.   30  30  15  28  28  28
Abbreviations: U, unadjusted; UA, creatinine adjusted.
Table 6. Significant correlations between car age 
and urinary phthalate metabolite concentrations at 
visit 1 (n = 30).
Variable  Spearman’s rho  p-Value
MECPP  –0.37  < 0.05
MEHHP  –0.39  0.03
MEOHP   –0.39  0.03
MiBP   –0.36  < 0.05
Table 7. Significant correlations between serum 
glucose concentrations and urinary phthalate 
metabolite concentrations at visit 1.
Variable  No.  Spearman’s rho  p-Value
MEHP  30  0.43  0.02
MECPP  33  0.35  < 0.05
MEHHP  33  0.37  0.03
MEOHP  33  0.38  0.03
Table 8. Significant correlations between serum 
triglycerides and urinary phthalate metabolites at 
visit 1.
Variable  No.  Spearman’s rho  p-Value
MEHP  30  0.48  < 0.01
MECPP  33  0.44  0.01
MEHHP  33  0.41  0.02
MEOHP  33  0.42  0.01Phthalate metabolites in lactating NC women
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Swan et al. (2005) found that in human male 
infants, anogenital distance, previously found 
to be a sensitive marker of antiandrogen activ-
ity in rodents, was inversely related to urinary 
concentrations of some phthalates during preg-
nancy. Wolff et al. (2008) found that low-
molecular-weight urinary phthalate metabo  lites 
(as measured in the third trimester of preg-
nancy) were positively correlated with gesta-
tional age and head circumference of newborn 
children. Recent analyses of NHANES data 
revealed positive correlations between urinary 
phthalate metabolite concentrations and glu-
cose and obesity-related end points (Hatch 
et al. 2008; Stahlhut et al. 2007).
In this study, MECPP was the most fre-
quently detected metabolite in serum, with a 
mean value of 2 µg/L; other oxidative phtha-
late metabolites are not above LOQ in most 
serum samples (78–97% not detected). Other 
human studies have reported serum phthalate 
monoester concentrations in Chinese work-
ers with occupational phthalate exposure (Pan 
et al. 2006).
Our results demonstrate that phthalate 
metabolites are unlikely to be detectable in 
milk and saliva. However, serum MECPP and 
urinary phthalate metabolites (except MMP) 
are informative end points for evalua  tion of the 
exposure to lactating women, but this informa-
tion does not translate into lactational expo-
sure to the infant. Those phthalate metabolites 
that were detectable showed several potentially 
important relationships with questionnaire or 
biologic end points.
Biomonitoring of phthalates in human 
populations has revealed differences among 
racial/ethnic groups (Silva et al. 2004; Wolff 
et al. 2007). In this study, whites had lower 
mean MECPP serum concentrations than did 
nonwhites (2.1 and 5.0 µg/L, respectively) at 
visit 1, but because 91% of the participants 
were white, this result has low statistical power. 
In NHANES 1999–2000, urinary concentra-
tions of MEP were significantly higher in non-
Hispanic blacks than in other race/ethnicity 
groups, and in non-Hispanic black children 
than in non-Hispanic white and Mexican-
American children (Silva et al. 2004). In 
another study, white adolescent girls had lower 
concentrations of MEHP and MEP but higher 
concentrations of MCPP than did other race/
ethnicity groups (Asian, black, and Hispanic) 
(Wolff et al. 2007). Consensus in racial differ-
ences across studies may be due to differences 
between ethnic groups in phthalate-metabo-
lizing enzymes, specifically polymorphisms in 
UDP-glucuronyltransferase genes (de Wildt 
et al. 1999; Dirven et al. 1993), but too few 
nonwhites participated in the present study for 
us to explore this interesting possibility.
Self-reported nail polish use showed a 
strong relation to untransformed urinary MEP 
concentrations, and several metabolites were 
associated with nail polish use after log trans-
formation (MBP, MBzP, MECPP, MEHHP, 
MEOHP, and the sum of DEHP metabolites). 
Personal care products, including nail polish, 
have been reported to contain diethyl phtha-
late (DEP), the parent compound of MEP 
(Kamrin and Mayor 1991). It is also possible 
that this metabolite reflects that women who 
used nail polish also used perfume and other 
personal care products that may contain DEP 
(Houlihan et al. 2002; Hubinger and Harvery 
2006; Koo and Lee 2004). Similar to the 
present study, Duty et al. (2005) found that 
personal care product use predicted urinary 
MEP concentrations in a cohort of men and 
that MEP increased for each additional type of 
product used. A recent pediatric study found 
increased urinary phthalate metabolite levels in 
infants after topical application of baby prod-
ucts, including lotions, soaps, and powders 
(Sathyanarayana et al. 2008). We also found 
an inverse correlation between primary motor 
vehicle age and urinary phthalate metabolite 
concentrations, including MiBP and the oxi-
dative metabolites of DEHP. Phthalates have 
been previously reported to be found in indoor 
and personal air (Adibi et al. 2008; Rudel et al. 
2003), which could explain an inhalation route 
of exposure.
We and others have found correlations 
between phthalate metabolites and serum 
glucose concentrations. In two recent studies, 
analyses of NHANES urinary phthalate metab-
olites found correlations between certain phtha-
late monoester or oxidative metabolites and 
abdominal obesity or homeostasis model assess-
ment index (HOMA), a biomarker for insulin 
resistance (Hatch et al. 2008; Stahlhut et al. 
2007). We found increased MECPP concen-
trations in serum for mothers with self-reported 
maternal gestational diabetes (n = 2) compared 
with the other mothers, and serum glucose 
levels were correlated with DEHP metabolite 
concentrations (visit 1: serum MECPP and 
urinary MECPP, MEHHP, and MEOHP). 
Hatch et al. (2008), Stahlhut et al. (2007), and 
our data all showed correlations of glucose-
related outcomes with DEHP metabolites, 
including MEHHP and MEOHP. Although 
we did not measure the health outcomes that 
were addressed in those prior studies, similar 
concentrations of the phthalate metabolites 
were observed in all three studies, suggesting 
that environmentally relevant exposure levels 
may translate into health-related outcomes. 
Future research in this area needs to address 
mechanisms for these health outcomes.
In the present study, serum triglycerides 
and DEHP metabolites were also correlated. 
Studies in mice have reported that subchronic 
or chronic phthalate exposure leads to increased 
serum and/or liver tri  glycerides (Mapuskar 
et al. 2007; Pereira et al. 2006). Acute expo-
sures to DEHP and/or di(n-hexyl)phthalate in 
rodents is associated with decreased triglycer-
ide levels (Howarth et al. 2001). A rat study 
using an intermediate dosing regimen of 21 
days found a decrease in total triglycerides that 
was mediated via lipase induction (Mocchiutti 
and Bernal 1997). Therefore, it appears that 
dose and duration of phthalate exposure in the 
rodent models differentially regulated serum 
triglyceride levels, but these associations have 
not been explored in humans.
In this study, we also found a correlation 
between serum IgA concentration (Hines et al. 
2007) and urinary MBP concentration. The 
role of phthalates as immunomodulators is 
just beginning to be explored. Genetically sus-
ceptible mice developed autoimmunity after 
DEHP exposure (Lim and Ghosh 2005). The 
association of phthalates with epidemologic 
respiratory immunity changes is highly debated 
(Doelman et al. 1990; Jaakkola et al. 1999; 
Mendell 2007; Oie et al. 1997). Studies in 
other labs have shown up-regulation of the 
immunosuppressive FK506 binding pro-
tein family of genes, specifically FKBP-1 and 
FKBP-13, after diisononyl phthalate exposure 
in rodents (Valles et al. 2003).
Finally, earlier work has shown that human 
urinary phthalate concentrations vary over the 
course of a day (Janjua et al. 2008). Women 
in this study visited the clinic between 0900 
hr and 1400 hr, and this window could lead 
to some temporal variability. However, there 
were no significant differences in total phtha-
late metabolite load or DEHP metabolite load 
of our participants across visits to the clinic. 
In fact, we found significant correlations of 9 
of the 10 phthalate urinary metabolites with 
themselves between visits when reported with-
out creatinine adjustment. Taking the findings 
of all of these studies into consideration, the 
use of a single sample collection to define con-
tinuing phthalate exposure may be adequate to 
reflect average phthalate exposure.
Conclusions
In lactating NC women, we found detectable 
concentrations of oxidative phthalate metabo-
lites in very few breast milk samples. Further, 
these same women had detectable concentra-
tions of oxidative and hydrolytic monoester 
phthalate metabolites in nearly all of their urine 
samples, detectable concentrations of MECPP 
in > 80% of their serum samples, and almost no 
detectable concentrations of phthalate metabo-
lites in their saliva. Thus, surrogate fluid meas-
ures (i.e., urine, serum, saliva) are not a good 
proxy measure for milk levels. In particular, 
high urinary metabolite levels do not predict 
detectable phthalates in human milk.
We examined the relationship of urinary 
metabolites, serum MECPP, questionnaire, and 
other biologic measures. The concentrations of 
DEHP metabolites showed significant correla-
tion, pointing to a common parent compound Hines et al.
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for exposure. Interestingly, metabolism-related 
end points (glucose and triglycerides) were sig-
nificantly associated with phthalate metabolite 
concentrations. Potential sources of phthalate 
exposure such as nail polish use and newer 
cars were significantly associated with increased 
concentrations of some phthalate metabolites. 
The total and DEHP-derived phthalate loads 
for study participants were not significantly 
different over time. Further, it appears that a 
single sampling may accurately represent aver-
age environmental phthalate exposure to the 
mother.
Breast milk is a superior source of infant 
nutrition with social, economic, and nutri-
tional benefits. The infrequent detection of 
measurable oxidative phthalate metabolites in 
milk, even in women with multiple metabo-
lites in their urine, supports continued efforts 
to promote breast-feeding worldwide.
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